A Phase 1 interventional study of MK-7262 and Enlicitide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MK-7262 orally.
Drug: MK-7262
Participants will receive enlicitide orally.
Drug: Enlicitide
Participants will receive MK-7262 and enlicitide orally.
Drug: MK-7262 · Drug: Enlicitide
Oral administration
Oral administration
Also known as: enlicitide decanoate, MK-0616
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262
Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days)
AUC0-inf of Enlicitide
Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Maximum Plasma Concentration (Cmax) of MK-7262
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Cmax of Enlicitide
Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262
Blood samples will be collected at multiple time points to estimate the AUC0-24 of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 24 hours post-dose)
Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262
Blood samples will be collected at multiple time points to estimate the AUC0-last of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Time to Maximum Plasma Concentration (Tmax) of MK-7262
Blood samples will be collected at multiple time points to estimate the Tmax of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Terminal Half-life (t1/2) of MK-7262
Blood samples will be collected at multiple time points to estimate the t1/2 of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Clearance (CL/F) of MK-7262
Blood samples will be collected at multiple time points to estimate the CL/F of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Apparent Volume of Distribution During Terminal Phase (Vz/F)of MK-7262
Blood samples will be collected at multiple time points to estimate the Vz/F of MK-7262.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
AUC0-24 of Enlicitide
Blood samples will be collected at multiple time points to estimate the AUC0-24 of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 24 hours post-dose)
AUC0-last of Enlicitide
Blood samples will be collected at multiple time points to estimate the AUC0-last of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Tmax of Enlicitide
Blood samples will be collected at multiple time points to estimate the Tmax of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
t1/2 of Enlicitide
Blood samples will be collected at multiple time points to estimate the t1/2 of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
CL/F of Enlicitide
Blood samples will be collected at multiple time points to estimate the CL/F of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Vz/F of Enlicitide
Blood samples will be collected at multiple time points to estimate the Vz/F of enlicitide.
Time frame: Predose and at designated time points post-dose (up to 8 days post-dose)
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.
Time frame: Up to approximately 8 weeks
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.
Time frame: Up to approximately 6 weeks
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2026 to primary completion in Sep 2026, 2 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide